Sensyne Health has signed a research project with Roche. Initially the collaboration will focus on identifying patient populations in one disease area and assessing and collating anonymized patient data with anonymized electronic patient record (EHR) information to support clinical trial planning. No financial terms were disclosed.
The planned collaboration will be Sensyne Health’s second successive partnership with a major pharmaceutical company following the announcement in July 2019 of a collaboration agreement with Bayer to accelerate the clinical development of new treatments for cardiovascular disease.
“This is an important collaboration and marks Sensyne’s increasing activity in partnering with leading pharmaceutical companies using our clinical AI platform,” Lord (Paul) Drayson PhD, CEO of Sensyne Health said. “It is particularly pleasing given Roche’s progressive approach to data and technology-driven personalized healthcare.”